NCT04007406View on ClinicalTrials.gov

DP13 - A Phase II Study in Patients With Primary Aldosteronism

PHASE2CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

May 2, 2022

Study Completion Date

May 2, 2022

Conditions

Primary Aldosteronism

Interventions

DRUG

dexfadrostat phosphate

DP13 systemic administration

Trial Locations (1)

10126

Ospedale Molinette, Torino

Sponsors

Lead Sponsor

Damian Pharma AG

All Listed Sponsors

lead

Damian Pharma AG

INDUSTRY